Product Description
Mechanisms of Action: CFTR Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Kingdom | United States | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: Vertex
Company Location: BOSTON MA 02210
Company CEO: Reshma Kewalramani
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 19
Highest Development Phases
Phase 3: Cystic Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VX21-121-105 | P3 |
Recruiting |
Cystic Fibrosis |
2030-06-30 |
77% |
| VX22-121-106 | P3 |
Enrolling by invitation |
Cystic Fibrosis |
2029-07-30 |
77% |
| VX22-445-123 | P3 |
Enrolling by invitation |
Cystic Fibrosis |
2027-09-30 |
46% |
| VX22-445-123 | P3 |
Recruiting |
Cystic Fibrosis |
2027-08-19 |
46% |
| VX21-121-105 | P3 |
Not yet recruiting |
Cystic Fibrosis |
2027-08-02 |
|
| VX21-445-125 | P3 |
Active, not recruiting |
Cystic Fibrosis |
2027-04-06 |
37% |
| VX21-445-125 | P3 |
Active, not recruiting |
Cystic Fibrosis |
2027-04-06 |
37% |
| VX20-121-104 | P3 |
Active, not recruiting |
Cystic Fibrosis |
2026-10-01 |
33% |
| VX20-445-112 | P3 |
Active, not recruiting |
Cystic Fibrosis |
2026-04-30 |
46% |
| VX22-121-106 | P3 |
Recruiting |
Cystic Fibrosis |
2025-10-31 |
77% |
| VX22-445-122 | P3 |
Active, not recruiting |
Cystic Fibrosis |
2025-10-06 |
34% |
| VX22-445-122 | P3 |
Active, not recruiting |
Cystic Fibrosis |
2025-10-06 |
34% |
| VX20-445-112 | P3 |
Active, not recruiting |
Cystic Fibrosis |
2025-06-20 |
|
| VNZ/TEZ/D-IVA | P1 |
Completed |
Cystic Fibrosis |
2024-05-23 |
12% |
| VX23-121-011 | P1 |
Completed |
Cystic Fibrosis |
2024-04-16 |
12% |
| 2020-002239-31 | P3 |
Active, not recruiting |
Cystic Fibrosis |
2024-02-18 |
46% |
| VX21-445-124 | P3 |
Completed |
Cystic Fibrosis |
2023-07-05 |
67% |
| VX20-445-119 | P3 |
Completed |
Cystic Fibrosis |
2023-03-24 |
76% |
| VX21-121-008 | P1 |
Completed |
Cystic Fibrosis |
2023-03-16 |
69% |